BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27799511)

  • 1. High-Risk of Adverse Pathologic Features in Patients With Clinical T1 High-Grade Bladder Cancer Undergoing Radical Cystectomy.
    Matulewicz RS; Frainey BT; Oberlin DT; Meeks JJ
    J Natl Compr Canc Netw; 2016 Nov; 14(11):1403-1411. PubMed ID: 27799511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?
    Tully KH; Cole AP; Krimphove MJ; Friedlander DF; Mossanen M; Herzog P; Noldus J; Sonpavde GP; Trinh QD
    Urology; 2021 Jan; 147():199-204. PubMed ID: 32805294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
    Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
    BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.
    Turker P; Bostrom PJ; Wroclawski ML; van Rhijn B; Kortekangas H; Kuk C; Mirtti T; Fleshner NE; Jewett MA; Finelli A; Kwast TV; Evans A; Sweet J; Laato M; Zlotta AR
    BJU Int; 2012 Sep; 110(6):804-11. PubMed ID: 22321341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis.
    Bruins HM; Aben KK; Arends TJ; van der Heijden AG; Witjes AJ
    Urol Oncol; 2016 Apr; 34(4):166.e1-6. PubMed ID: 26705102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy.
    Moschini M; Morlacco A; Briganti A; Hu B; Colombo R; Montorsi F; Frank I; Daneshmand S; Karnes RJ
    Eur Urol Focus; 2018 Mar; 4(2):245-251. PubMed ID: 28753820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
    Viers BR; Boorjian SA; Frank I; Tarrell RF; Thapa P; Karnes RJ; Thompson RH; Tollefson MK
    Eur Urol; 2014 Dec; 66(6):1157-64. PubMed ID: 24630414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.
    Klaassen Z; Kamat AM; Kassouf W; Gontero P; Villavicencio H; Bellmunt J; van Rhijn BWG; Hartmann A; Catto JWF; Kulkarni GS
    Eur Urol; 2018 Nov; 74(5):597-608. PubMed ID: 30017405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does patient age affect survival after radical cystectomy?
    Horovitz D; Turker P; Bostrom PJ; Mirtti T; Nurmi M; Kuk C; Kulkarni G; Fleshner NE; Finelli A; Jewett MA; Zlotta AR
    BJU Int; 2012 Dec; 110(11 Pt B):E486-93. PubMed ID: 22551360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?
    Segal R; Yafi FA; Brimo F; Tanguay S; Aprikian A; Kassouf W
    BJU Int; 2012 Apr; 109(7):1026-30. PubMed ID: 21883838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy.
    Gupta A; Lotan Y; Bastian PJ; Palapattu GS; Karakiewicz PI; Raj GV; Schoenberg MP; Lerner SP; Sagalowsky AI; Shariat SF;
    Urology; 2008 Feb; 71(2):302-7. PubMed ID: 18308108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
    Soave A; John LM; Dahlem R; Minner S; Engel O; Schmidt S; Kluth LA; Fisch M; Rink M
    Urology; 2015 Jul; 86(1):92-8. PubMed ID: 26051839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effect on survival of pelvic lymph node dissection at radical cystectomy for muscle invasive bladder cancer.
    Larcher A; Sun M; Schiffmann J; Tian Z; Shariat SF; McCormack M; Saad F; Fossati N; Abdollah F; Briganti A; Buffi N; Graefen M; Guazzoni G; Montorsi F; Karakiewicz PI
    Eur J Surg Oncol; 2015 Mar; 41(3):353-60. PubMed ID: 25477269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes.
    Mason RJ; Frank I; Bhindi B; Tollefson MK; Thompson RH; Karnes RJ; Tarrell R; Thapa P; Boorjian SA
    World J Urol; 2017 Dec; 35(12):1879-1884. PubMed ID: 28913657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
    Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
    Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy.
    Sonpavde G; Khan MM; Svatek RS; Lee R; Novara G; Tilki D; Lerner SP; Amiel GE; Skinner E; Karakiewicz PI; Bastian PJ; Kassouf W; Fritsche HM; Izawa JI; Ficarra V; Dinney CP; Lotan Y; Fradet Y; Shariat SF
    BJU Int; 2011 Sep; 108(5):687-92. PubMed ID: 21087453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
    Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
    Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience.
    Moschini M; Karnes RJ; Sharma V; Gandaglia G; Fossati N; Dell'Oglio P; Cucchiara V; Capogrosso P; Shariat SF; Damiano R; Salonia A; Montorsi F; Briganti A; Gallina A; Colombo R
    Eur J Surg Oncol; 2016 May; 42(5):735-43. PubMed ID: 26927300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer.
    Guzzo TJ; Magheli A; Bivalacqua TJ; Nielsen ME; Attenello FJ; Schoenberg MP; Gonzalgo ML
    Urology; 2009 Dec; 74(6):1276-80. PubMed ID: 19758684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer.
    Koppie TM; Serio AM; Vickers AJ; Vora K; Dalbagni G; Donat SM; Herr HW; Bochner BH
    Cancer; 2008 Jun; 112(11):2384-92. PubMed ID: 18404699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.